Tests BAY 3547926, a radioactive drug, in advanced liver cancer
Tests a radioactive drug, BAY 3547926, in adults with advanced liver cancer.
Key facts
- Who runs it
- Bayer
- Where
- Glasgow, London, and Sutton, United KingdomSee the 3 sitesAlso in 8 other countries, 28 sites
- Trial code
- Registry title
- A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 148 people, planned
- Started
- 28 Feb 2025
- Expected to end
- 31 Aug 2031
- Type of study
- Interventional
- Treatments tested
- BAY 3547926
- BAY 3547922
- BAY 3713391
- BAY 3713389
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced liver cancer (hepatocellular carcinoma) whose tumour shows the protein GPC3. It tests the safety of a new drug, BAY 3547926.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC), confirmed by tissue or cell tests or, in people with confirmed cirrhosis, by AASLD criteria. At least one lesion that can be measured on CT or MRI. ECOG performance status 0 or 1.
- Earlier treatment
- Disease cannot be treated with, or has progressed after, surgery meant to remove all of the disease or local treatments such as resection, local ablation or chemoembolization.
- Biomarker or test result
- Tumour sample must test positive for GPC3 by immunohistochemistry, confirmed centrally.
Main reasons for not taking part
- Fibrolamellar HCC, sarcomatoid HCC or mixed hepatocellular/cholangiocarcinoma
- History or clinical signs of CNS metastases, unless specific criteria are met
- Encephalopathy of Grade 2 or higher within the past 12 months
- Clinically significant ascites
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Locally advanced or metastatic and/or unresectable HCC (hepatocellular carcinoma) with histological or cytological confirmation, or non-invasive diagnosis as per American Association for the Study of Liver Diseases (AASLD) criteria in participants with a confirmed diagnosis of cirrhosis
- Demonstrated positive centrally confirmed GPC3 expression by immunohistochemistry (IHC) on tumor sample
- Disease not amenable to, or progressive disease after, curative surgery and/or locoregional therapies of established efficacy such as resection, local ablation, chemoembolization
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1
- At least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. as assessed by local site Investigator within 28 days prior to the start of the study treatment
- Adequate bone marrow and organ function
Who cannot take part
- History of encephalopathy ≥ Grade 2 within the past 12 months
- Fibrolamellar HCC, sarcomatoid HCC, and mixed hepatocellular/cholangiocarcinoma subtypes
- Participants with a history or clinical evidence of CNS metastases, unless they meet specific criteria
- Clinically significant ascites
Where in United Kingdom
Also in 8 other countries, 28 sites
- GlasgowGlasgow, United KingdomTaking people
- LondonLondon, United KingdomTaking people
- SuttonSutton, United KingdomTaking people
About the trial
What the trial wants to find out
In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein called Glypican 3 (GPC3). Researchers want to find the best dose of BAY 3547926 for people with advanced HCC and look at the way the body absorbs and distributes the drug.
Read full original descriptionShow less
The study drug, BAY 3547926, delivers a radioactive agent to cancer cells. The radioactive agent emits radiations which can damage the cancer cells and cause them to die. These radiations travel a small distance, so are expected to cause little damage to surrounding healthy tissues. This is the first study of BAY 3547926 in humans.
Participants will take part in one of the 4 different parts of the study. In Part 1, participants will receive different doses of BAY 3547926 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3547926 alone in Part 2 or with other treatments in Parts 3 and 4 of the study.
During the study, the doctors and their study team will do health check-ups, take pictures (scans) of the body, collect blood and urine samples, and ask participants questions about how they are feeling and what health problems they are having.
The group in the trial
- BAY 3547926Treatment being tested
actinium-225 labeled antibody conjugate
Treatment: BAY 3547926, BAY 3547922, BAY 3713391, and BAY 3713389
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Multicenter, Open Label, Non-randomized First-in-human Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BAY 3547926 Alone, and in Combination, in Participants With Advanced Hepatocellular Carcinoma (HCC)
- Plain-language title
- Tests BAY 3547926, a radioactive drug, in advanced liver cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 October 2026